Escherichia coli on colorectal cancer: A two‐edged sword
Microbial Biotechnology · 2024-10 · 17 (10)
DOI: 10.1111/1751-7915.70029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 14.10.2024. Verfasst von Chu Jian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Escherichia coli, Gastrointestinal Microbiome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Public Welfare Technology Application Research Program of Huzhou, China University Industry University Research Innovation Fund, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Escherichia coli ( E. coli ) is a ubiquitous symbiotic bacterium in the gut, and the diversity of E. coli genes determines the diversity of its functions. In this review, the two‐edged sword theory was innovatively proposed. For the question ‘how can we harness the ambivalent nature of E. coli to screen and treat CRC?’, in terms of CRC screening, the variations in the abundance and subtypes of E. coli across different populations present an opportunity to utilise it as a biomarker, while in terms of CRC treatment, the natural beneficial effect of E. coli on CRC may be limited, and engineered E. coli , particularly certain subtypes with probiotic potential, can indeed play a significant role in CRC treatment. It seems that the favourable role of E. coli as a genetic tool lies not in its direct impact on CRC but its potential as a research platform that can be integrated with various technologies such as nanoparticles, imaging methods, and synthetic biology modification. The relationship between gut microflora and CRC remains unclear due to the complex diversity and interaction of gut microflora. Therefore, the application of E. coli should be based on the ‘One Health’ view and take the interactions between E. coli and other microorganisms, host, and environmental factors, as well as its own changes into account. In this paper, the two‐edged sword role of E. coli in CRC is emphasised to realise the great potential of E. coli in CRC screening and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang, People's Republic of China.
- Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, Zhejiang, People's Republic of China.
- Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, Zhejiang, People's Republic of China.
- Huzhou University, Huzhou, Zhejiang, People's Republic of China.
- ASIR (Institute - Association of intelligent systems and robotics), Rueil-Malmaison, France.
ORCID-Profile: Han Shuwen
Förderung
- Public Welfare Technology Application Research Program of Huzhou
- China University Industry University Research Innovation Fund
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Jian, C., Yinhang, W., Jing, Z., Zhanbo, Q., Zefeng, W., & Shuwen, H. (2024). Escherichia coli on colorectal cancer: A two‐edged sword. Microbial Biotechnology, 17(10). https://doi.org/10.1111/1751-7915.70029
Vancouver
Jian C, Yinhang W, Jing Z, Zhanbo Q, Zefeng W, Shuwen H. Escherichia coli on colorectal cancer: A two‐edged sword. Microbial Biotechnology. 2024;17(10). doi:10.1111/1751-7915.70029
BibTeX
@article{Jian2024,
author = {Jian, Chu and Yinhang, Wu and Jing, Zhuang and Zhanbo, Qu and Zefeng, Wang and Shuwen, Han},
title = {Escherichia coli on colorectal cancer: A two‐edged sword},
journal = {Microbial Biotechnology},
year = {2024},
volume = {17},
number = {10},
doi = {10.1111/1751-7915.70029}
}
EUVIMED